Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Search

Top

Battelle National Biodefense Institute 505 King Avenue COLUMBUS OH 43201 USA

UEI: SLED_5D64285098E39921

Battelle National Biodefense Institute 505 King Avenue COLUMBUS OH 43201 USA is a federal contractor, registered under UEI SLED_5D64285098E39921. It has been awarded $480,569,440 across 1 federal contract. Primary work spans Research and Development in Biotechnology. Top awarding agencies include Contract Administration Svcs Division.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_5D64285098E39921

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Contract Administration Svcs Division$480.6M100%

Awards by NAICS

541711 - Research and Development in Biotechnology$480.6M100%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in Battelle National Biodefense Institute 505 King Avenue COLUMBUS OH 43201 USA's top NAICS codes and agencies

Biosafety & Recombinant DNA Research ComplianceThe U.S. Air Force, under the U.S. Department of Defense, is seeking a subcontract for Biosafety and Recombinant DNA Research Compliance. The primary objective of this engagement is to ensure strict adherence to federal biosafety regulations and to provide necessary support for Institutional Biosafety Committee approval regarding research involving recombinant DNA molecules. This opportunity is designated as a Total Small Business Set-Aside under the SBIR/STTR mandate for companies with fewer than 500 employees, falling under NAICS code 541711. The solicitation was posted on August 26, 2026, with a response deadline of September 9, 2026, at 4:00 PM.

POSTED

DEADLINE

Technical R&D Execution in Specialized DomainsThe U.S. Air Force, under the Department of Defense, is seeking a subcontractor to perform applied research and development within specialized technical domains, including artificial intelligence, machine learning, biotechnology, materials science, and unmanned systems. This effort is conducted under Phase I Small Business Innovation Research awards to advance critical technological capabilities. This opportunity is a total small business set-aside, requiring participants to have fewer than 500 employees to comply with SBIR/STTR mandates. The solicitation was posted on August 26, 2026, with a response deadline of September 9, 2026. The work falls under NAICS code 541711 for research and development in the physical, engineering, and life sciences.

POSTED

DEADLINE

Novel In-Situ Binder Chemistry Development

NASA SBIR/STTR Program

POSTED

DEADLINE

Candidate Influenza Vaccine Virus (CVV) Development

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Data Collection & Analytics for Lunar MissionsThe National Aeronautics And Space Administration, specifically the Space Operations Mission Directorate, is seeking a subcontractor to develop data collection frameworks and analytical models focused on health metrics. This initiative is designed to monitor and analyze astronaut health during lunar missions ranging from short-duration stays to month-long deployments. The opportunity was posted on August 11, 2026, with a response deadline of September 8, 2026. Classified under NAICS code 541711, the project emphasizes the creation of robust systems to ensure the well-being of crew members during extended lunar operations.

Space Operations Mission Directorate

POSTED

DEADLINE

Pharmaceutical-Based Agent (PBA) Detection Systems

POSTED

DEADLINE

Integrated Phase I/II Clinical Trial DesignThe contract seeks the design and protocol development for an integrated Phase I/II clinical trial to evaluate ibogaine as a potential treatment for opioid use disorder, focusing on safety, optimal dosing, and therapeutic efficacy. The effort requires a comprehensive clinical framework that seamlessly merges the objectives of Phase I, which prioritizes dose escalation and toxicity profiling, with those of Phase II, which assesses preliminary effectiveness in reducing opioid dependence and withdrawal symptoms. The protocol must adhere to rigorous scientific and regulatory standards, incorporating appropriate patient selection criteria, monitoring procedures, endpoints, and risk mitigation strategies for a substance with significant pharmacological and safety considerations. The work is being pursued as a subcontract under the Advanced Research Projects Agency for Health, part of the Department of Health and Human Services, with a NAICS code indicating research and development in the life sciences. The solicitation was posted on August 5, 2026, and responses are due by October 15, 2026. The project is situated within a broader initiative to advance novel therapeutic interventions for the opioid crisis, requiring innovative trial design that balances exploratory research with clinical feasibility. There is no specified set-aside designation or location restriction for performance, indicating flexibility in execution while emphasizing scientific merit and regulatory alignment as key evaluation criteria.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

in about 2 months

Phage-Based Formulation Development

W6QK Acc Ccdc Sttc

POSTED

DEADLINE

High-Throughput Yeast Two-Hybrid ScreeningA large-scale yeast two-hybrid screening project is being sought to identify protein-protein interactions between viral bait proteins and aphid prey libraries, encompassing all necessary laboratory procedures including yeast transformation and interaction assays. The effort is designed to enable high-throughput discovery of molecular connections critical to understanding viral infection dynamics in aphid hosts, with the goal of advancing agricultural pest and disease control strategies. This subcontract is designated as a Small Business Set Aside under NAICS code 541711, reserved exclusively for small business concerns, and is managed by the USDA Agricultural Research Service through its Albany Facility. The opportunity was posted on August 4, 2026, with a firm response deadline of August 28, 2026, and the performance location is specified as Ithaca, New York, with a zip code of 14853. The contract type and set-aside status emphasize support for small business participation in federally funded scientific research aimed at improving agricultural outcomes.

USDA Ars Afm Apd

POSTED

DEADLINE

in about 17 hours

Aphid cDNA Prey Library DevelopmentThe contract involves the development of a normalized cDNA library from aphid RNA supplied by the government, specifically for use in yeast two-hybrid prey systems. The work includes reverse transcription of the RNA into complementary DNA and subsequent cloning procedures to generate a high-quality, representative library that enables effective protein-protein interaction screening. The project is designed to support biological research efforts by providing a standardized, scalable prey library that enhances the reliability and depth of interaction data in functional genomics studies. This subcontract is designated as a Small Business Set Aside under the NAICS code 541711, indicating it is reserved for small businesses engaged in research and development in the life sciences. The work is to be performed in Ithaca, New York, with a response deadline of August 28, 2026, and was posted on August 4, 2026. The contracting entity is the USDA Agricultural Research Service, Agricultural Facilities Management and Application Personnel Division, and the project is intended to advance USDA’s mission in agricultural biotechnology and pest research through innovative molecular tools.

USDA Ars Afm Apd

POSTED

DEADLINE

in about 17 hours

Viral Bait Clone ConstructionThe contract involves the design and molecular cloning of viral protein bait constructs specifically for use in yeast two-hybrid systems, requiring comprehensive molecular biology expertise including codon optimization for host compatibility, precise plasmid insertion, and rigorous sequence validation to ensure accuracy and functionality. The work focuses on creating reliable protein baits that enable the study of virus-host protein interactions, which is critical for understanding pathogenic mechanisms and identifying potential therapeutic targets. All constructs must meet high standards of precision to support downstream functional assays in a controlled laboratory environment. The contract is designated as a Small Business Set Aside under NAICS code 541711 for scientific research and development, with performance to be carried out in Ithaca, New York, at the USDA ARS AFM APD facility. It was posted on August 4, 2026, and responses are due by August 28, 2026, with a clear emphasis on delivering technically robust and validated molecular reagents within the specified timeframe. The scope demands a high level of technical proficiency in molecular cloning, sequence analysis, and bioinformatics tools, with deliverables expected to support ongoing virology and host-pathogen interaction research funded by the U.S. Department of Agriculture.

USDA Ars Afm Apd

POSTED

DEADLINE

in about 17 hours

Clinical Trial Design and Efficacy Data GenerationThe contract calls for the design and execution of clinical trials aimed at evaluating the safety, wound closure, infection control, and functional regeneration outcomes of medical interventions in patients with burn and trauma injuries. The work requires rigorous scientific methodology to generate robust efficacy data that supports regulatory and clinical adoption, with a focus on measurable endpoints related to tissue recovery and patient outcomes. The trials must be conducted in accordance with established clinical standards and are intended to provide evidence of therapeutic effectiveness under real-world conditions. This is a subcontract under the Aspr Administration for Strategic Preparedness and Response, part of the Department of Health and Human Services, with a solicitation posted on July 28, 2026, and a response deadline of August 28, 2026. The work is classified under NAICS code 541711, indicating research and development in the life sciences. The performance location is designated with a zip code of 77416, though no specific city or state is provided, and no point of contact details are listed. The contract does not include a set-aside designation, and all eligible entities may respond, with emphasis placed on technical capability, trial design expertise, and experience in trauma and burn clinical research.

Aspr Administration For Strategic Preparedness And Response

POSTED

about 1 month ago

DEADLINE

in about 15 hours

Preclinical Animal Studies for Neurofibromatosis ResearchThe contract seeks to conduct preclinical in vivo studies using genetically engineered mouse models or alternative animal models of neurofibromatosis to assess the efficacy of therapeutic interventions, track tumor progression, and investigate underlying biological mechanisms. The work requires advanced expertise in animal modeling, tumor biology, and preclinical drug evaluation, with a focus on generating robust, reproducible data to support future clinical translation. All studies must be conducted in accordance with established ethical and scientific standards for animal research, with detailed documentation of methodologies, outcomes, and adverse events. This subcontract is issued under the Defense Health Agency Contracting Activity and falls under NAICS code 541711, indicating it supports research and development in the physical, engineering, and life sciences. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is open to qualified entities capable of executing complex preclinical studies. While the place of performance and point of contact details are unspecified, successful proposers must demonstrate capacity to manage animal facilities, comply with regulatory requirements, and deliver high-quality, timely results in support of neurofibromatosis research objectives under the Department of Defense.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

Collaborative Biomedical Research ExecutionThis contract enables a collaborative biomedical research effort focused on neurofibromatosis, requiring coordinated hypothesis-driven investigations led by an Initiating Principal Investigator and a Partnering Principal Investigator. The work encompasses the design of experiments, generation of empirical data, and rigorous milestone-based progress reporting to ensure scientific rigor and accountability. The project is structured as a subcontract under the Defense Health Agency Contracting Activity, falling under the NAICS code for research and development in the physical, engineering, and life sciences, and is intended to advance understanding of neurofibromatosis through integrated scientific contributions. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is managed by the Department of Defense through its health research infrastructure. While no set-aside provisions or specific location details are provided, the emphasis is firmly on outcome-driven research with clearly defined deliverables tied to research milestones. The effort requires close alignment between the two principal investigators to ensure cohesive experimental planning, data integrity, and timely reporting, reflecting a strategic investment in translational medical science with potential implications for defense-relevant health conditions.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

Collaborative Research Partnership (Partnering PI Option)This contract establishes a collaborative research partnership where a Partnering Principal Investigator from an external institution will co-lead the research effort alongside the primary team, sharing equal responsibility for scientific direction, project management, and deliverables. Funding is jointly allocated between the participating institutions, ensuring aligned resources and mutual accountability for outcomes, with the work focused on health-related research under the Defense Health Agency Contracting Activity. The initiative falls under NAICS code 541711, indicating it is within the scientific research and development sector, and is structured as a subcontract to support integrated, multi-institutional innovation. The opportunity was posted on June 18, 2026, with a deadline for responses set for September 28, 2026, providing potential partners a defined window to submit proposals. The partnership is expected to be conducted in alignment with the mission of the Department of Defense, addressing critical health priorities through joint scientific leadership. There is no set-aside designation specified, meaning eligibility is open to qualified institutions regardless of size or status, and no specific location is designated for performance, allowing flexibility in where the research activities are carried out as long as the objectives are met collaboratively.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

in about 1 month

Kidney Cancer Clinical Research ExecutionThe contract titled Kidney Cancer Clinical Research Execution aims to advance clinical and translational research focused on kidney cancer through comprehensive scientific activities including study design, patient data collection, biomarker analysis, and therapeutic development. The work is intended to support the development of innovative treatments and diagnostic strategies by integrating clinical observations with laboratory research, ensuring findings are rapidly translated into improved patient outcomes. The project requires expertise in oncology research methodologies, rigorous data management, and interdisciplinary collaboration to address critical gaps in kidney cancer understanding and care. This subcontract is issued by the Defense Health Agency Contracting Activity under the Department of Defense and falls under NAICS code 541711, indicating it is related to research and development in the life sciences. The opportunity was posted on June 18, 2026, with a response deadline of September 28, 2026, providing potential applicants approximately three months to prepare and submit proposals. The place of performance and specific office address details are not specified, suggesting flexibility in location but requiring proposers to align with the overarching objectives of the Department of Defense’s medical research priorities. All work must demonstrate scientific excellence, feasibility, and direct relevance to advancing kidney cancer therapeutics within a clinical context.

Defense Health Agency Contracting Activity - Dhaca

POSTED

DEADLINE

in about 1 month

Clinical Trial Design and Biostatistical SupportThe contract seeks specialized expertise to support clinical trial design and biostatistical analysis for orthopaedic trauma research funded by the Department of Defense, specifically under the U.S. Army Medical Research and Acquisition Activity. The work involves developing robust clinical trial methodologies, crafting statistical analysis plans, performing power analyses to ensure adequate sample sizes, and establishing data monitoring frameworks to ensure trial integrity and compliance with regulatory standards. Support must be tailored to the unique challenges of military-relevant trauma studies, including patient populations, deployment-related injuries, and the operational constraints of DoD medical settings. The opportunity is structured as a subcontract with a NAICS code of 541711, indicating it falls under research and development in the physical, engineering, and life sciences. The solicitation was posted on June 17, 2026, and responses are due by November 18, 2026. Performance is expected to occur within the broader DoD infrastructure, though no specific location is designated. There is no set-aside classification specified, and the contract is open to qualified entities capable of delivering high-level biostatistical and clinical trial methodological support in a defense medical research context.

Department Of The Army -- Usamraa

POSTED

DEADLINE

Preclinical Biomedical Research on Traumatic Orthopaedic InjuriesThis contract requires the conduct of preclinical biomedical research focused on bone healing, tissue regeneration, and orthopaedic trauma models using animal systems, with the goal of advancing medical solutions aligned with military needs. The work involves designing controlled experiments, collecting longitudinal data on injury response and recovery, and performing rigorous statistical and biological analysis to evaluate therapeutic interventions. All research must be tailored to simulate combat-related orthopaedic injuries and produce actionable insights applicable to field medical care and soldier recovery protocols. The effort is structured as a subcontract under the Department of the Army through USAMRAA, with a solicitation posted on June 17, 2026, and a response deadline of November 18, 2026. The project falls under NAICS code 541711 for research and development in the physical, engineering, and life sciences. Performance location and point of contact details are not specified, but the research must be executed in facilities capable of supporting high-standard animal modeling and biomechanical analysis. The ultimate objective is to generate validated preclinical data to inform the development of next-generation treatments for traumatic injuries sustained in military operations.

Department Of The Army -- Usamraa

POSTED

DEADLINE